Background Dexamethasone 6 mg daily for 10 days is the recommended treatment for
patients with severe or critical coronavirus disease 2019 (COVID-19). The evidence on the …

Introduction The impact of different doses of dexamethasone on outcomes from acute
COVID-19 pneumonia is unknown. Methods We performed a systematic review and meta …

Background Low-dose dexamethasone demonstrated clinical improvement in patients with
coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the …

Background Despite the proven benefits of dexamethasone in hospitalized coronavirus
disease 2019 (COVID-19) patients, the optimum time for the administration of …

Importance Limited effective therapeutics are available to hospitalized patients with COVID-
19. Clinical trials and observational studies have shown varying effects of systemic …

Background and objectives Corticosteroids are commonly used in the treatment of
hospitalized patients with COVID-19. The goals of the present study were to compare the …

Background Dysregulated systemic inflammation is the primary driver of mortality in severe
coronavirus disease 2019 (COVID-19) pneumonia. Current guidelines favour a 7–10-day …

A clinical interpretation of the Randomized Evaluation of COVID-19 Therapy (RECOVERY)
study was performed to provide a useful tool to understand whether, when, and to whom …

Objective To determine whether high-dose dexamethasone increases the number of
ventilator-free days (VFD) among patients with acute respiratory distress syndrome (ARDS) …

ABSTRACT Background Coronavirus disease 2019 (COVID-19) is associated with diffuse
lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing …